Introduction
The European Society of Human Reproduction and Embryology (ESHRE) PGD Consortium was established in 1997. Its major objectives are to establish guidelines, to promote best practice and to collect data on PGD cycles, pregnancies, deliveries and children. Four guidelines on different aspects of PGD (organization of a PGD centre, FISH-based testing, amplification-based testing and biopsy) have been written (Harton et al., 2011a,b,c,d) . To date, 13 extensive data collections have been published, covering all applications of PGD, including monogenic diseases, HLA typing and chromosome abnormalities, PGS and social sex selection (Geraedts et al., 1999 (Geraedts et al., , 2000 ESHRE PGD Consortium Steering Committee, 2002; Sermon et al., 2005 Sermon et al., , 2007 Harper et al., 2006 Harper et al., , 2008b Harper et al., , 2010b Goossens et al., , 2012 Moutou et al., 2014; De Rycke et al., 2015) . An overview has been presented after 10 years of data collection (Harper et al., 2012) . In this 14th report, data were exceptionally collected from two consecutive calendar years instead of a single year. Data were collected from cycles carried out in 2011-2012 with follow-up of pregnancies and babies born until October 2013.
Materials and Methods
Participating centres anonymously reported data on PGD/PGS cycles, pregnancies and babies in separate files using a FileMaker Pro database (versions 5-12) . The blank FileMaker Pro files were distributed to each PGD Consortium member centre. A preliminary analysis of the submitted data allowed the identification of omissions and any ambivalent data entries. Records with incomplete or inconsistent data were excluded from the calculations. The different files were then assigned to expert coauthors for an in-depth analysis, followed by calculations and presentation of results in tables.
Clinical pregnancies were defined as the presence of one or more foetal hearts at 6 weeks of gestation. Implantation rate was defined as the number of foetal hearts per 100 embryos transferred. Delivery rate was defined as the percentage of pregnancies with delivery per oocyte retrieval procedure (OR) and per embryo transfer procedure.
Results
Only data from centres with a full PGD Consortium membership were taken into account, as only these members can provide full information on all aspects of PGD. This report includes data from 71 centres. The results are represented in tables according to an established lay out. Accompanying text is deliberately concise and four tables are available in an electronic version only: Supplementary Tables SVIIIa (data I-XIII) and SVIIIb (data XIV-XV) list the complications of pregnancy and Supplementary Tables SXIIa (data I-XIII) and SXIIb (data XIV-XV) list the congenital malformations and the neonatal complications. Cumulative data of all cycles collected previously in data collections I-XIII can be found in Table Ia , while an overview of the current data collection can be found in Table Ib . The data for social sexing (38 cycles) have not been reported in this last table and tables with detailed data (Tables VIa and  VIb) have been omitted as well, see below. For all PGD/PGS cycles (11 637 cycles to OR), ICSI was the method most often used for fertilization (10 530/11 637, 90%). For all cycles to biopsy (11 481), zona pellucida drilling was more commonly performed using a laser (9136/11 481, 80%) and cleavage-stage aspiration was the preferential stage/method for biopsy (8735/11 481, 76%) (Table Ib) . Overall, blastocyst biopsy was reported in a minority of cases (471/11 481, 4%). Table IIb summarizes the 1953 cycles with OR for data collection XIV-XV. In 169 (9%) cycles, PGD for a structural chromosome abnormality was performed simultaneously with aneuploidy screening, a slight increase as compared with data XIII in which 6% of cycles had PGS as second indication. In 17 cycles, PGD was performed simultaneously for an additional structural chromosomal abnormality (16 cycles) or a monogenic indication (1 cycle).
PGD cycles for structural chromosomal abnormalities
As for all years (cumulative data shown in Table IIa) , data XIV-XV showed that PGD for reciprocal translocations was performed more often than for any other type of structural chromosome abnormality (62%). For reciprocal translocations, the number of cycles performed for female carriers was very similar as that for male carriers, whereas for Robertsonian translocations (27%), the number of cycles performed for male carriers was about 1.6-fold that of female carriers.
Mean female age was 35 years, a figure that shows little variation over the years. In 80% of all cycles to OR, ICSI was used for fertilization, similar to data XIII. Nearly all cycles to OR (96%) reached the biopsy stage. The use of laser drilling for zona breaching covered 76% of all cycles. Aspiration of blastomeres from cleavage-stage embryos remained the preferred biopsy method (83% versus 89% in data collection XIII). Biopsy at the blastocyst stage was implemented for the first time (from less than 1% in data XIII up to 7% of cycles in data XIV-XV). The use of FISH as method of analysis decreased from 93% in data XIII to 85% in the current data collection, in favour of the use of array technology, which increased from 6% to 13% between 2010 and 2012.
For data XIV-XV, 24 578 oocytes were collected, a mean of 12.6 per cycle. Of these, 61% (15 056/24 578) were fertilized (2 pronuclei) and 76% (11 404/15 056) of the resulting embryos were biopsied. Of the embryos successfully biopsied, 94% (10 475/11 103) gave a diagnostic result, of which only 24% (2481/10 475) were transferable. This was in line with previous years (data I-XIII) where a mean of 13.3 oocytes per cycle were collected and 26% of diagnosed embryos were genetically transferable. As expected, the lowest percentage of transferable embryos was found in the reciprocal translocation group (19% for male or female carriers). Of all transferable embryos, 72% were actually transferred and 17% were frozen.
From 1953 cycles to OR, only 61% resulted in an embryo transfer procedure. This is in agreement with previous data (embryo transfer in 64% of cycles to OR; data I-XIII 4450/6968) showing that a high level of chromosomally abnormal embryos is found in patients carrying chromosomal abnormalities.
A positive hCG was obtained in 478 cycles, with a positive heartbeat in 372 cycles (19% per OR and 31% per embryo transfer). The poorest outcome, 12% positive heartbeat per OR, was found in the group of deletion carriers. This is linked with the lowest percentage of transferable embryos available for this group. Overall, the implantation rate was 24% (419/1776) and the delivery rate was 15% per OR (287/ 1953) and 24% per embryo transfer procedure (287/1196). There were 57 miscarriages and 28 clinical pregnancies were lost to followup. Implantation and delivery rates have remained stable over the last years: the clinical pregnancy rate for data I-XIII is 18% per OR and 28% per embryo transfer procedure. Tables IIIa and IIIb summarize the 1484 and 144 cycles to OR collected for data collections I-XIII and XIV-XV, respectively. As holds true for the PGD cycles for a chromosomal abnormality, the majority of cycles for X-linked diseases was performed with ICSI (66%), laser drilling (86%) and biopsy by cleavage-stage aspiration (91%). FISH was still the most frequently used method (78% of cycles); PCR was applied in 15% and whole genome amplificaton/arrays in 6% of cycles.
PGD cycles for sexing for X-linked diseases
For data XIV-XV, 1616 oocytes were collected (a mean of 11.2 per OR), 70% (990/1424) of inseminated oocytes were fertilized and 79% (785/990) of the resulting embryos were biopsied. Of the embryos successfully biopsied, 96% (728/759) gave a diagnostic result, of which only 35% (255/728) were transferable. From 255 transferable embryos, 148 were actually transferred in 107 cycles (74% of cycles to OR). A positive hCG was obtained in 50 cycles, with a positive heartbeat in 40 cycles. This yielded a clinical pregnancy rate of 28% per OR and 37% per embryo transfer, which was a better result in comparison to the cumulative data I-XIII (20% per OR and 26% per ET). This gave an implantation rate of 27% (40/148). Finally, the delivery rate was 20% per OR (29/ 144) and 27% per embryo transfer (29/107). There were two miscarriages and nine clinical pregnancies were lost to follow-up. 
PGD cycles for monogenic diseases
Tables IVa and IVb summarize the 9267 and 3445 cycles to OR collected for data collection I-XIII and XIV-XV, respectively. For data XIV-XV, ICSI was used in the majority of cycles (99% of cycles to OR) and PCR was still the most widely used first-line method of DNA amplification (93%). The use of laser was the preferred method for biopsy (81% of cycles to PGD); acidic Tyrode's or mechanical action was applied in 8% and 11% of cycles to PGD, respectively (versus 15% and 10% respectively in data XIII). These results indicate that the application of mechanical biopsy remained constant whereas the use of acidic Tyrode's has decreased in favour of laser. Day 3 cleavage-stage embryo biopsy was most frequently used (93% of cycles to PGD) while the use of blastocyst biopsy remained low (2%). These results were very similar to the previous data collection. Genetic testing was carried out on either one blastomere (58% of cycles to PGD with Day 3 biopsy) or two blastomeres per embryo (28% of cycles to PGD with Day 3 biopsy). This is an improvement compared to the previous data collection, with 43% of 1-cell biopsy cycles and 37% of 2-cell biopsy cycles. A total number of 44 771 cumulus oocyte complexes (COC) were collected and 76% of mature oocytes that were injected actually fertilized. A total of 79% of fertilized embryos were biopsied with a 97% success rate. Of the embryos successfully biopsied, 91% gave a diagnostic result. From 3402 PGD procedures, 80% resulted in an embryo transfer. Per cycle to OR on average 13.0 COCs were collected with 10.7 mature oocytes for injection. This yielded on average 8.1 fertilized embryos. Per PGD cycle on average 6.5 embryos were suitable for biopsy. Diagnosis was achieved for 5.8 embryos. On average 1.3 embryos were transferred while 0.7 embryos were used for cryopreservation, which was very similar to data XIII. 
Preimplantation genetic screening
Overall, 6095 PGS cycles were reported in data collection XIV-XV (Table Vb) . The mean age of women undergoing PGS was 39 years, which is the same as in data collection XIII but slightly higher than the mean age of 37 years observed in the cumulative data of previous collections I-XIII (Table Va) . The most common indications for PGS were advanced maternal age (40%), repeated implantation failure (12%) as a single indication or in combination either with advanced maternal age (12%) or with recurrent miscarriage (10%) and severe male factor (9%). Other indications were previous abnormal pregnancies, individuals with abnormal karyotypes, including mosaicism for numerical chromosomal abnormalities and couples with more than one indication. A small number of couples underwent PGS following oocyte donation or without a reported medical indication. Second indication PGS (n = 30), reciprocal male carrier (n = 1). b Second indication PGS (n = 31). c Second indication PGS (n = 45), robertsonian male carrier (n = 3), inversion (n = 5), monogenic disease (n = 1). d Second indication PGS (n = 31), robertsonian male carrier (n = 3), inversion (n = 3). The majority of biopsies (67%) were performed at cleavage stage; blastocyst biopsy was carried out in only 4% of cycles. Laser biopsy was the preferred method (80%); acidic Tyrode's or mechanical zona breaching was applied in 9% and 11% of cycles to PGS, respectively. For the genetic analysis FISH was used in 68% of cases while arrays were used in 20% of cases ( Continued transferrable, 72% were actually transferred and 17% were frozen. This was in accordance with the cumulative data (Table Va) where 34% (45 090/131 267) of diagnosed embryos were transferable and 74% (33 332/45 090) were used for transfer while 14% were cryopreserved. Overall, of 6095 cycles that reached OR, 3763 (62%) had an embryo transfer and a positive hCG was obtained in 1488 cycles, with a positive heartbeat in 1261 cycles, yielding a clinical pregnancy rate of 21% per OR or 34% per embryo transfer procedure. This was slightly better than the overall clinical pregnancy rates from data I-XIII (20% per OR and 28% per embryo transfer). There were 816 reported deliveries, and 231 clinical pregnancies were lost to follow-up. The overall delivery rate was 13% per cycle to OR and 22% per cycle to embryo transfer. The overall miscarriage rate per clinical pregnancy was 21% for all indications, ranging from 8% for advanced maternal age combined with severe male factor or oocyte donation and severe male factor to 35% for advanced maternal age in combination with repeated IVF failure.
PGD cycles for social sexing
The number of reported cycles for social sexing in data XIV-XV was similar to previous data collections, accounting for less than 1% (38/ 11 675) of all cycles submitted. Details on 705 cycles for social sexing were reported in data I-XII. Because social sexing as an indication for PGD is debatable, from data XIII onwards, only cycle numbers were included in the reports. Tables VIIa, VIIb Table VIIb) ; which is in accordance with previously published data collections. Of the 2147 clinical pregnancies presenting with a positive heartbeat, follow-up data on 1231 pregnancies were reported. There were 91/1231 complications in pregnancy reported (Supplementary Table SVIIIb ). The delivery rates per indication were reported in Tables IIb, IIIb, IVb, Vb and VIb. Caesarean section was performed for 44% of the deliveries (765/1755) ( Table IXb) . In 315 cases, the method of delivery was not known. Confirmation of the diagnosis was performed prenatally in 506 cases, and/or post-natally in 590 cases (Table Xb) . In 10 cases, a chromosomal abnormality was found, not related to the indication for PGD. Table Xb  and Supplementary Table SXIIb describe the data on congenital malformations, neonatal complications and perinatal deaths. In 1585 out of 2066 cases (77%) the information on malformations found during pregnancy was lacking, and in 1674 out of 2066 liveborns (81%) the information on neonatal malformations was lacking. In 26 out of 481 cases (5%), a minor-and/or major-malformation(s) was reported. Of these cases, 11 resulted in termination of pregnancy (TOP). In 6% of the reported cases a neonatal complication occurred (Supplementary Table SXIIb) .
Pregnancies and babies
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Misdiagnoses

Discussion
In order that the data are up to date, this 14th data report of the ESHRE PGD Consortium involves data from two consecutive calendar years instead of a single year. The most time-consuming step in data processing involves data 'cleaning': inconsistent data are clarified or missing data are added following contact between the relevant centre and the science manager of ESHRE. As data analysis had fallen behind, it was decided to reduce this laborious part and omit inconsistent and incomplete data. This is the main reason for the higher percentages of follow-up losses in cycles, pregnancies and children born. This may also explain why the total number of reported cycles has remained constant compared to data XIII, while it is clear from the European Good is defined ≥7, poor is defined <7.
IVF-Monitoring ESHRE Consortium data that the number of reported PGD/PGS cycles increased from 6399 (2010) to 6824 (2011) and to 8433 (2012) (Kupka et al., 2014 (Kupka et al., , 2016 Calhaz-Jorge et al., 2016) . Another reason, especially true for missing pregnancy and baby data, is that adequate follow-up of these aspects was not in place in many centres. Nevertheless, the number of participating centres (71) was higher than for the previous data collection XIII (62). Data submission is a time-consuming activity and the steering committee acknowledges the effort of all contributing centres. Up to data XIII, the number of PGS cycles had increased annually but by 2010 a number of RCTs had clearly demonstrated that routine PGS using FISH at cleavage stage was not beneficial. The number of PGS cycles had decreased from 58% in data XII to 52% in data XIII and it has remained constant for the 2 years of the current data collection. A consensus was published by the ESHRE PGD Consortium stating that future studies with alternative biopsy timing and genetic testing were necessary to evaluate the clinical benefit of PGS (Harper et al., 2010a) . Data XIV-XV showed that genetic testing with genome-wide arrayCGH instead of FISH was applied in 20% of PGS cycles, but this
was not yet linked with blastocyst biopsies. The uptake of arrayCGH was also observed in PGD cycles for chromosomal abnormalities, although less prominent than for PGS, and it was associated with the implementation of Day 5-6 biopsies. Techniques such as arrayCGH provide a generic platform, avoiding the need to develop locus-and family-specific tests, but consumables and equipment are expensive. It may take some time before workflows and instruments have been adapted and the personnel have been adequately trained. Turning from Day 3 to Day 5-6 biopsy requires an optimal embryo culture system and may lead to problems of limited time for analysis in case of fresh embryo transfer. This can be overcome by cryopreservation and embryo transfer in a deferred cycle. Again, such strategies require adaptations in laboratory organization and personnel training, explaining why the switch towards genome-wide genetic testing and blastocyst biopsy is not more advanced yet.
No further misdiagnosis cases were reported in this data collection. Although data reporting is anonymous, it may be that centres do not wish to reveal this information. Another explanation may be further improvement of laboratory quality management systems. The preceding years have seen an increased implementation of accreditation together with the first PGD external quality assessment schemes carried out from 2009 onwards (Deans et al., 2013) . To date, including all cycles up to data XIV-XV, misdiagnosis has been reported for only 13/12 790 PCR-based cycles, 21/40 640 FISH-based PGD cycles and no data yet on the new genome-wide technologies. As many embryo transfers have no follow-up (no pregnancy or birth), and only a minority of centres perform audit through re-analysis of untransferred/noncryopreserved supernumerary embryos, the numbers reported in the data collections may not reflect the true misdiagnosis in PGD.
The evaluation and publication of data collections have been lagging. PGD and PGS cycles have become more complex and the FileMaker Pro database system, created before 2000, is no longer adequate to further monitor data and trends in PGD services. Therefore this data collection is the last to be published relying on FileMaker Pro files. The retrospective data from 2013 to 2015 will be published as summary data, while a new platform for prospective data collection has been launched in June 2017 to handle data from 2016 onwards. This on-line platform is analysis-based instead of cycle-based and collects data over the various segments of OR, biopsy, analysis, transfer, pregnancy and babies, taking into account that PGD cycles are no longer carried out within the timeframe of a single procedure.
Supplementary data
Supplementary data are available at Human Reproduction online.
